Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
Radiopharm Theranostics (ASX:RADX) has appointed renowned medical oncologist Dr Oliver Sartor to its Scientific Advisory Board. Dr Sartor currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the Mayo Clinic.
Dr Sartor brings extensive experience in prostate cancer research and radiopharmaceutical therapies, having authored over 500 peer-reviewed publications and led multiple pivotal Phase 3 trials resulting in FDA approvals. His previous roles include positions at Tulane Cancer Center, LSU Health Sciences Center, and Dana-Farber/Harvard Medical School.
Radiopharm Theranostics (ASX:RADX) ha nominato il rinomato oncologo medico Dr Oliver Sartor nel suo Comitato Scientifico. Attualmente, il Dr Sartor è Direttore delle Sperimentazioni Cliniche sui Radiofarmaci e Presidente del Gruppo Malattie Oncologiche Genitourinarie presso la Mayo Clinic.
Il Dr Sartor vanta una vasta esperienza nella ricerca sul cancro alla prostata e nelle terapie radiofarmaceutiche, avendo pubblicato oltre 500 articoli peer-reviewed e guidato numerosi studi di Fase 3 fondamentali che hanno portato alle approvazioni FDA. In passato ha ricoperto ruoli presso il Tulane Cancer Center, LSU Health Sciences Center e Dana-Farber/Harvard Medical School.
Radiopharm Theranostics (ASX:RADX) ha nombrado al reconocido oncólogo médico Dr Oliver Sartor en su Consejo Asesor Científico. Actualmente, el Dr Sartor es Director de Ensayos Clínicos con Radiofármacos y Presidente del Grupo de Enfermedades de Cáncer Genitourinario en la Mayo Clinic.
El Dr Sartor aporta una amplia experiencia en investigación del cáncer de próstata y terapias con radiofármacos, habiendo publicado más de 500 artículos revisados por pares y liderado múltiples ensayos clave de Fase 3 que resultaron en aprobaciones de la FDA. Anteriormente, ocupó cargos en el Tulane Cancer Center, LSU Health Sciences Center y Dana-Farber/Harvard Medical School.
Radiopharm Theranostics (ASX:RADX)는 저명한 의료 종양학자 Dr Oliver Sartor를 과학 자문 위원회에 임명했습니다. Sartor 박사는 현재 Mayo Clinic에서 방사성 의약품 임상 시험 책임자이자 비뇨기계 암 질환 그룹 의장을 맡고 있습니다.
Sartor 박사는 전립선암 연구 및 방사성 의약품 치료 분야에서 풍부한 경험을 보유하고 있으며, 500편 이상의 동료 검토 논문을 저술하고 FDA 승인을 받은 여러 중요한 3상 임상시험을 주도했습니다. 이전에는 Tulane Cancer Center, LSU Health Sciences Center, Dana-Farber/Harvard Medical School에서 근무한 경력이 있습니다.
Radiopharm Theranostics (ASX:RADX) a nommé le célèbre oncologue médical Dr Oliver Sartor à son Conseil Consultatif Scientifique. Le Dr Sartor est actuellement directeur des essais cliniques sur les radiopharmaceutiques et président du groupe de maladies du cancer génito-urinaire à la Mayo Clinic.
Le Dr Sartor apporte une vaste expérience dans la recherche sur le cancer de la prostate et les thérapies radiopharmaceutiques, ayant publié plus de 500 articles évalués par des pairs et dirigé plusieurs essais de phase 3 majeurs ayant conduit à des approbations de la FDA. Il a précédemment occupé des postes au Tulane Cancer Center, au LSU Health Sciences Center et à la Dana-Farber/Harvard Medical School.
Radiopharm Theranostics (ASX:RADX) hat den renommierten medizinischen Onkologen Dr Oliver Sartor in seinen Wissenschaftlichen Beirat berufen. Dr Sartor ist derzeit Direktor für klinische Studien mit Radiopharmazeutika und Vorsitzender der Gruppe für urogenitale Krebserkrankungen an der Mayo Clinic.
Dr Sartor bringt umfassende Erfahrung in der Prostatakrebsforschung und Radiopharmazeutischen Therapien mit, hat über 500 begutachtete Fachpublikationen veröffentlicht und mehrere entscheidende Phase-3-Studien geleitet, die zu FDA-Zulassungen führten. Zuvor war er unter anderem am Tulane Cancer Center, LSU Health Sciences Center und Dana-Farber/Harvard Medical School tätig.
- Appointment of highly experienced medical oncologist with expertise in radiopharmaceutical therapies
- Addition of leader who has conducted multiple successful FDA-approval-leading trials
- Strengthening of scientific advisory capabilities in clinical translation
- None.
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company’s Scientific Advisory Board (SAB).
Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine.
Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology.
Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI).
Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy.
“Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,” said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. “We’re very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.”
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ
(Formerly Stern IR)
E: annemarie.fields@precisionaq.com
Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
FAQ
Who is Dr Oliver Sartor and why is his appointment significant for Radiopharm (RADX)?
What is Dr Oliver Sartor's current role at Mayo Clinic?
What are Dr Oliver Sartor's major achievements in clinical research?
What is Radiopharm Theranostics' (RADX) main business focus?
